全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Willi Cawello , Bjoern Burckhardt
来源:[J].Drug Design, Development and Therapy(IF 3.486), 2019, Vol.2019 (default), pp.481-490Dove
摘要:IntroductionComparative pharmacokinetic (PK) data analysis of drugs administered using developed child-appropriate and market authorized dosage formulation is sparse and is important in pediatric drug development.ObjectivesTo compare and evaluate any differences in PK of ena...
作者:... Jens-Otto Andreas , Marina Braun , Willi Cawello
来源:[J].Clinical Therapeutics(IF 2.23), 2015, Vol.37 (4), pp.902-912Elsevier
摘要:Abstract(#br)Purpose(#br)Rotigotine, a nonergolinic dopamine receptor agonist, is a once-daily transdermal patch developed for the treatment of Parkinson’s disease and restless legs syndrome. The objective of the present study was to determine the pharmacokinetic characteris...
作者:Willi Cawello , Jens-Otto Andreas ...
来源:[J].Drugs(IF 4.633), 2015, Vol.75 (5), pp.487-501Springer
摘要:Abstract(#br)This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D3/D2/D1 dopamine receptor agonist approved for the treatment of early- and advanced-stage Parkinson’s disease (PD...
作者:... Jens-Otto Andreas , Michelle Middle , Willi Cawello
来源:[J].Clinical Therapeutics(IF 2.23), 2012, Vol.34 (4), pp.966-978Elsevier
摘要:Abstract(#br)Background(#br)The dopamine agonist rotigotine is formulated in a transdermal delivery system (patch) for once-daily application. It has been reported as efficacious in the treatment of idiopathic Parkinson's disease (PD) and restless legs syndrome.(#br)Objectiv...
作者:Willi Cawello , Marina Braun , Jens-Otto Andreas
来源:[J].European Journal of Drug Metabolism and Pharmacokinetics(IF 0.944), 2018, Vol.43 (4), pp.475-481Springer
摘要:Abstract(#br) Background and Objective(#br)Pharmacokinetic studies using deconvolution methods and non-compartmental analysis to model clinical absorption of drugs are not well represented in the literature. The purpose of this research was (1) to define the system of equati...
作者:Willi Cawello , Carina Schäfer
来源:[J].Epilepsy Research(IF 2.241), 2014, Vol.108 (6), pp.1068-1075Elsevier
摘要:Summary(#br)Purpose(#br)Frequent plasma sampling to monitor pharmacokinetic (PK) profile of antiepileptic drugs (AEDs), is invasive, costly and time consuming. For drugs with a well-defined PK profile, such as AED lacosamide, equations can accurately approximate PK parameter...
作者:Willi Cawello , Christa Mueller-Voessing , Andreas Fichtner
来源:[J].Clinical Drug Investigation(IF 1.915), 2014, Vol.34 (5), pp.317-325Springer
摘要:Abstract(#br) Background(#br)The antiepileptic drug lacosamide has a low potential for drug–drug interactions, but is a substrate and moderate inhibitor of the cytochrome P450 (CYP) enzyme CYP2C19.(#br) Objective(#br)This phase I, randomized, open-label, two-way crossover tr...
作者:Willi Cawello , Seong Ryul Kim ...
来源:[J].European Journal of Drug Metabolism and Pharmacokinetics(IF 0.944), 2016, Vol.41 (4), pp.353-362Springer
摘要:Abstract(#br)Rotigotine is a dopamine receptor agonist indicated for the treatment of Parkinson’s disease and moderate-to-severe restless legs syndrome. Continuous transdermal delivery of rotigotine via a silicon-based patch maintains stable plasma concentrations over 24 h. ...
作者:Willi Cawello , Andreas Fichtner ...
来源:[J].European Journal of Drug Metabolism and Pharmacokinetics(IF 0.944), 2014, Vol.39 (3), pp.155-163Springer
摘要:Abstract(#br)The transdermally applied dopamine receptor agonist rotigotine is extensively metabolized in the liver. An open-label, parallel-group study was conducted to evaluate the effects of moderate hepatic impairment on the pharmacokinetics, safety and tolerability of r...
作者:Willi Cawello
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2015, Vol.54 (9), pp.901-914Springer
摘要:Abstract(#br)Lacosamide—a third-generation antiepileptic drug available in multiple formulations—was first approved in 2008 as adjunctive therapy for partial-onset seizures (POS) in adults. In 2014, lacosamide was approved as monotherapy for POS by the US Food and Drug Admin...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×